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Hsp90 is one of the most conserved molecular chaperones 
ubiquitously expressed in normal cells and over-expressed in 
cancer cells. A pool of Hsp90 was found in cancer mitochon-
dria and the expression of the mitochondrial Hsp90 homolog, 
TRAP1, was also elevated in many cancers. The mitochondrial 
pool of chaperones plays important roles in regulating mi-
tochondrial integrity, protecting against oxidative stress, and 
inhibiting cell death. Pharmacological inactivation of the chap-
erones induced mitochondrial dysfunction and concomitant 
cell death selectively in cancer cells, suggesting they can be 
target proteins for the development of cancer therapeutics. 
Several drug candidates targeting TRAP1 and Hsp90 in the mi-
tochondria have been developed and have shown strong cyto-
toxic activity in many cancers, but not in normal cells in vitro 
and in vivo. In this review, recent developments in the study 
of mitochondrial chaperones and the mitochondria-targeted 
chaperone inhibitors are discussed [BMB reports 2012; 45(1): 
1-6]
INTRODUCTION
After exposure to proteotoxic insults such as heat and oxida-
tive stresses, cells elevate the expression of a set of proteins, 
collectively called heat shock proteins (Hsp), as a protective 
mechanism (1). The inducible heat shock proteins and their 
cognate constitutively expressed members are recognized as 
molecular chaperones (2). The most fundamental functions of 
these chaperones are to fold and maintain the proper con-
formation of other proteins, named clients, and to guard them 
from misfolding and aggregation, consequently regulating the 
cellular function of clients (3). The 90-kDa heat shock protein, 
Hsp90, is one of the most conserved heat shock proteins, 
found in bacteria and all eukaryotes, and is ubiquitously ex-
pressed in cells (4, 5). Hsp90 is an essential component of the 
protective heat shock responses, and participates in stabilizing 
and regulating many client proteins involved in cellular signal-
ing networks (6). 
　Cancer cells reside in harmful and stressful environments, 
wherein they express higher levels of Hsp90 and other chaper-
one molecules than normal cells, in order to sustain viability 
(3). Hsp90 is critical for tumor cells to tolerate the stressful en-
vironments which induce protein unfolding, and to maintain 
the function of accumulated mutant proteins produced during 
tumorigenesis (6, 7). Many client proteins stabilized by Hsp90 
in cancer cells are associated with, and regulate, the proteins 
in tumorigenic signaling pathways related to cell proliferation, 
evasion of apoptosis, gene replication, angiogenesis, and meta-
stasis (8). Due to this nodal regulatory function of Hsp90 in 
malignant transformation, Hsp90 has become a target protein 
for development of anticancer therapeutics (9). Various classes 
of Hsp90 inhibitors have been developed, and some of them 
are already in clinical trials (10). 
　The Hsp90 family in mammalian cells is composed of 4 ma-
jor homologs: Hsp90α (inducible form) and Hsp90β (con-
stitutive form) are cytosolic isoforms; the 94kDa glucose-regu-
lated protein (GRP94) is localized to the endoplasmic retic-
ulum, and TRAP1 resides in the mitochondrial matrix (6, 11). 
In this review, recent progress concerning mitochondrial 
Hsp90 studies associated with cytoprotective functions in can-
cer cells, and the development of mitochondria-targeted in-
hibitors will be discussed. 
TRAP1: HOMOLOGOUS TO Hsp90 BUT FUNCTIONA-
LLY DIFFERENT FROM Hsp90 
The tumor necrosis factor (TNF) receptor-associated protein 1 
(TRAP1), alternatively known as heat shock protein 75 
(Hsp75), was initially identified as an Hsp90 homolog interact-
ing with the TNF receptor (12) and the retinoblastoma protein 
(Rb), irrespective of mitochondrial location (13). However, 
subsequent careful analyses of the TRAP1 cDNA sequence 
and subcellular localization using biochemical and micro-
scopic techniques have proven the existence of a mitochon-
drial targeting sequence at its N-terminal end and mitochon-
drial accumulation of the protein (14). 
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TRAP1 is a mitochondrial homolog of Hsp90
Hsp90 has 3 domains which are resistant to proteolysis; the 
N-terminal domain, the middle segment, and the C-terminal 
domain, or briefly, the N, M, and C domains (4). TRAP1 and 
Hsp90 share conserved domain architectures with high amino 
acid sequence similarity, molecular chaperone functions, and 
homo-dimeric quaternary structures (11-13, 15). Apart from 
the structural similarity between them, TRAP1 has the addi-
tional mitochondrial targeting sequence at its N-terminus, 
which is cleaved off after mitochondrial translocation, and 
lacks the highly charged flexible region between the N and M 
domains of Hsp90 (11-13).
　The N domain contains an ATP binding site and is the most 
conserved region between Hsp90 and TRAP1 (12, 13). Both 
chaperones have ATPase activities and are inhibitable by a 
prototype Hsp90 inhibitor, geldanamycin, at a comparable 
working concentration (14). This indicates that Hsp90-targeted 
drugs designed to occupy the ATP pocket in the Hsp90 N do-
main can also inhibit the TRAP1 chaperone function in vitro. 
The common Hsp90 inhibitors, however, cannot compromise 
the function of TRAP1 in vivo due to its mitochondrial location 
(16, 17).
TRAP1 and Hsp90 in mitochondria have disparate properties 
compared to cytosolic Hsp90
Each organelle contains its own unique set of proteins and spe-
cialized distribution of biomolecules. Thus, though they are 
homologous to each other, TRAP1 in the mitochondrial micro-
environment could have different cellular functions from cyto-
solic Hsp90, due to the potential differential distribution of in-
teractors, such as clients and regulators of the chaperone lo-
cated inside and outside of the mitochondria. TRAP1 does not 
interact with the co-chaperones or the client proteins of Hsp90 
in vitro, which further implies the regulation and function of 
TRAP1 in mitochondria are different from those of Hsp90 (14). 
A pool of Hsp90 is also found inside mitochondria in various 
cancer cells and some normal mouse tissues (16), and is likely 
to be modulated differentially from cytosolic Hsp90 for the 
same reason. The mitochondrial Hsp90 does not form protein 
complexes with TRAP1, even though it is compartmentalized 
in the same place; the mitochondrial matrix (16). Considering 
no unique functions have been assigned to either of them at 
this point, TRAP1 and Hsp90 seem to work independently and 
be functionally redundant in mitochondria. 
THE FUNCTION OF TRAP1 AND Hsp90 IN MITOCHO-
NDRIA
TRAP1 is synthesized in the cytoplasm, translocated into the 
mitochondria, and maturated by cleaving off the N-terminal 
mitochondrial targeting sequence (18). A pool of mitochon-
drial TRAP1 seems to be exported from the mitochondria to in-
teract with extramitochondrial proteins such as a TNF receptor 
(12), retinoblastoma protein (13), and tumor suppressor EXT 
proteins (19). Even with a mitochondrial targeting sequence at 
their N-terminus, the extramitochondrial location of other mi-
tochondrial chaperones, such as Hsp60 and mortalin, is often 
found in many cancer cells (20). Whereas its functional roles 
in maintaining mitochondrial integrity in stressful environ-
ments and inhibiting cell death have been well documented, 
the exact export mechanism and cytoplasmic functions of 
TRAP1 are not fully understood. 
TRAP1 protects mitochondria from oxidative stresses
Excessive production of oxygen-containing reactive free radi-
cals induces oxidative stress and can be the cause of mi-
tochondrial dysfunction and cell death related to various hu-
man diseases, including neurodegeneration, heart attack, 
stroke, and cancers (21, 22). Much literature has demonstrated 
that TRAP1 plays an important role in inhibiting cell death 
caused by a reactive oxygen species (ROS) (23, 24). Silencing 
TRAP1 through siRNA increases ROS accumulation, whereas 
TRAP1 over-expression decreases ROS production (25, 26). 
Granzyme M, a serine protease capable of inducing apoptosis, 
can cleave TRAP1 to compromise the ATPase activity and 
abolish its antagonistic functions against ROSs, resulting in 
ROS accumulation and cell death (25). Thus, as a molecular 
chaperone, TRAP1 prevents damaged proteins from unfolding 
and refolds denatured proteins (27), regulates ROS metabolism 
to antagonize ROS production, and thereby maintains the in-
tegrity of the mitochondria under oxidative stress.
TRAP1 modulates the permeability transition pore to inhibit 
cell death
ROS production can trigger cell death by opening the perme-
ability transition (PT) pore in the mitochondrial inner mem-
brane (28). The pore opening results in the loss of mitochon-
drial inner membrane potential, mitochondrial swelling, and a 
concomitant rupture of the outer membrane, which results in 
necrotic or apoptotic cell death (29). Initially, the molecular 
identity of the PT pore had been considered to consist of the 
protein complex of the voltage-dependent anion channel 
(VDAC) and the adenine nucleotide translator (ANT), which 
are located in the mitochondrial outer and inner membranes, 
respectively (30). Later, it was clearly shown that the mi-
tochondrial PT pore was still operational, even after the genet-
ic deletion of VDAC or ANT genes, suggesting they are not the 
sole PT pore components (31, 32). In contrast to the ambig-
uous molecular identity of membranous PT pore components, 
a series of knockout mouse studies showed that a mitochon-
drial matrix protein, cyclophilin D (Cyp-D), plays an important 
role in the formation of the pore in the mitochondrial inner 
membrane (33-35). Cyp-D is a peptidyl-prolyl cis-trans isomer-
ase presumed to catalyze protein folding and is located in the 
mitochondrial matrix where it interacts with the PT pore com-
ponents in the inner membrane (36). Once activated under 
stress conditions, such as elevated ROS/calcium and depleted 
ATP, Cyp-D switches the conformation of proteins constituting 
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Fig. 1. Regulation of a PT pore in a mitochondrial inner mem-
brane (IM). Under normal physiological conditions, the Cyp-D in 
a mitochondrial matrix is inactive (black) and the PT pore is 
closed (black). Under stress conditions, the Cyp-D is activated 
(purple) and interacts with the PT pore components in the IM, 
which triggers opening of the pore (blue) and results in the in-
crease of non-selective permeability in the IM, swelling of the mi-
tochondria, rupture of the mitochondrial outer membrane, and 
concomitant induction of cell death. In cancer cells, however, 
though they are constantly exposed to the same unfavorable con-
ditions, the PT pores remain in a closed state due to the elevated 
expression of chaperones such as TRAP1 and Hsp90 in the mi-
tochondrial matrix, which inhibits the pore-forming function of the 
Cyp-D through direct interactions. 
the PT pore to generate non-selective pores through the mem-
brane (29). 
　TRAP1 and the mitochondrial pool of Hsp90 directly inter-
act with Cyp-D and modulate its function, i.e. inhibit the pore 
opening triggered by Cyp-D activation, which confers the vari-
ous cell types resistance to a variety of stresses, and is there-
fore an important survival mechanism in cancer cells (16, 37) 
(Fig. 1). The ATPase activity of the chaperones is critically in-
volved in the inhibition of Cyp-D function and concomitant PT 
pore formation. The protein-protein interaction between 
Hsp90/TRAP1 and Cyp-D, however, is not important because 
it was maintained even after treatment with inhibitors com-
promising the protective function of the mitochondrial 
Hsp90/TRAP1 (16). This indicates that the protein folding and 
refolding activities of the chaperones, not the protein inter-
action per se, seems to be critical in regulating Cyp-D func-
tions involving the conformational switch of PT pore 
components. 
Regulation of TRAP1 and mitochondrial Hsp90
Though the regulation of TRAP1 expression is not fully under-
stood, several lines of evidence suggest a close relationship be-
tween TRAP1 expression and tumorigenesis. Expression analysis 
with oligonucleotide microarrays revealed that TRAP1 is one of 
the target genes elevated by the Myc oncogene (38). TRAP1 was 
over-expressed in primary human fibroblasts and mouse pros-
tate by SV40-induced malignant transformation (39, 40). 
Various cancer cell lines, including mouse adenocarcinoma, 
and specimens from human cancer patients also consistently 
showed over-expression of TRAP1, while it remained un-
detectable in normal cells and tissues (16, 40). 
　The elevated expression of Hsp90 in the mitochondria of 
many cancer cells is readily observed (16). The transport mec-
hanism of cytoplasmic Hsp90 into the mitochondria, however, is 
currently unclear. It is possible that machineries involved in the 
preprotein import are modified to enhance the mitochondrial 
transport of Hsp90. This may be associated with the functional 
modifications of unidentified cytosolic regulatory factors regulat-
ing protein trafficking during malignant transformation (41). 
　Post-translational modification, such as phosphorylation, is 
an important means to regulate the protein function in vivo. 
Phosphorylation of TRAP1 by PTEN induced putative kinase 1 
(PINK1) is responsible for the protection of ROS mediated cell 
death (42). It is likely that a PINK1-TRAP1 pathway affects mi-
tochondrial integrity by regulating the Cyp-D function, but the 
potential regulatory pathway has not yet been fully investiga-
ted. In addition to phosphorylation, considering the regulation 
of Hsp90 functions by other post-translational modifications 
such as acetylation and nitrosylation in cytoplasm (43), we 
cannot exclude the possibility that such modifications also oc-
cur and critically affect the function of mitochondrial chaper-
ones under normal or pathological conditions. 
INHIBITORS TARGETING MITOCHONDRIAL TRAP1 
AND Hsp90 AS CANCER THERAPEUTICS
TRAP1 and mitochondrial Hsp90 critically inhibit cell death 
in cancer cells
Cancer cells are under stress conditions due to the insufficient 
supply of oxygen and an increased metabolic demand com-
pared to normal cells, which, without protective mechanisms, 
could easily trigger opening of the PT pore (29, 44). TRAP1 
over-expression can be one of the protective mechanisms 
adopted during tumor progression and is closely related to the 
multi-drug resistance commonly found in cancer cells (24, 45). 
Loss of the chaperone functions directly induce mitochondrial 
membrane permeabilization (MMP), followed by immediate 
cell death in many cancer cells, but not in normal cells. This 
strongly argues that the chaperone networks operate in a can-
cer-specific manner and can be the Achilles heel of many can-
cer cells (37). 
　Cytosolic Hsp90 has the role of chaperoning labile mutated 
proteins in cancer cells to allow them to be functional, other-
wise they are aggregated and inactivated (3). Similarly, ablation 
of the chaperone function of TRAP1 and mitochondrial Hsp90 
by pharmacological reagents or genetic methods increased ag-
gregation of many proteins in cancer mitochondria and trig-
gered unfolded protein responses (UPR). This further affected 
cytosolic survival pathways including NF-κB signaling and in-
creased the sensitivity to anticancer therapeutics (27, 46, 47), 
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Fig. 2. Mitochondria-targeted Hsp90/TRAP1 inhibitors. Both shep-
herdin and Ant-GA have an amino acid sequence of cell penetrat-
ing peptide, RQIKIWFQNRRMKWKK. Shepherdin contains an amino 
acid sequence from survivin, KHSSGCAFL, which is involved in the 
interaction with Hsp90, and Ant-GA has a prototype Hsp90 in-
hibitor, geldanamycin, to inhibit Hsp90 and TRAP1. Gamitrinib-G4 
and TPP adopted a modular structure: 1) mitochondrial targeting 
module, tetracyclicguanidinium or triphenylphosphonium, 2) Hsp90/ 
TRAP1 inhibition module, geldanamycin, and 3) linkers connecting 
both of them. 
Therefore, in addition to the intra-mitochondrial triggering of 
cell death programs, targeted inhibition of TRAP1 and Hsp90 
in mitochondria results in the perturbation of global survival 
pathways outside the mitochondria in cancer cells, further 
strengthening the rationale of targeting mitochondrial Hsp90 
and TRAP1 for cancer therapies.
Gamitrinibs accumulate in mitochondria and inhibit TRAP1 
and Hsp90
Widely used conventional Hsp90 inhibitors may be effective in 
inhibiting the function of mitochondrial TRAP1 and Hsp90, as 
long as they are delivered into the mitochondria. In practice, 
those inhibitors were unable to pass through the mitochondrial 
membranes, which suggests they neither affect the function of 
the chaperones therein, nor induce direct organelle dysfunction, 
i.e. MMP (37). To make them reach the target proteins and di-
rectly induce MMP, it is required to use a drug delivery system 
targeted to the mitochondria. Gamitrinibs are the first mitochon-
dria-targeted small molecules which inhibit TRAP1 and Hsp90 
inside the mitochondria (17). Gamitrinibs directly induced 
MMP, resulting in loss of mitochondrial inner membrane poten-
tial and discharge of cytochrome c into the cytosol, followed by 
extensive cell death in many cancer cells (17, 48, 49). 
　Gamitrinibs are composed of 3 modules: 1) a mitochondrial 
targeting module, cyclic guanidinium or triphenylphosphonium, 
2) the prototype Hsp90 inhibitor, geldanamycin, and 3) short 
linkers connecting between them (17). The design of Gamitrinibs 
was originated and developed from the peptide-based Hsp90 in-
hibitor, shepherdin, and the peptide-chemical hybrid compound, 
Ant-GA (Fig. 2). Both molecules use a cell penetrating peptide 
(CPP) sequence, helix III of the Antennapedia homeodomain 
protein, to pass through the plasma membrane and deliver the 
inhibitory sequence inside the cell, and unexpectedly, were de-
livered and accumulated inside the mitochondria (16, 50). 
　The major prominent difference between CPP-containing and 
mitochondria-targeted inhibitors is the effect on the Hsp90 in 
the cytoplasm. Gamitrinibs have no effect on cytosolic Hsp90, 
and thereby neither change client expression nor induce heat 
shock responses. Meanwhile, CPP-containing inhibitors com-
promise the function of cytoplasmic Hsp90, which, as a result, 
elevates the expression of Hsp70 as a heat shock response and 
degrades client proteins (17). Gamitrinibs show much improved 
anticancer activity compared to the CPP-containing shepherdin 
and Ant-GA when they are used to treat cancer cell types in vi-
tro or mouse tumor xenografts in vivo,  probably due to the ef-
fective accumulation of the drugs in the target organelle mi-
tochondria (16, 17). 
　Hence, when considering broad and selective cytotoxic ac-
tivities in various cancer cells in vitro and in vivo, targeting the 
mitochondrial chaperone is a feasible strategy to develop a 
novel class of anticancer drugs such as Gamitrinibs, with po-
tent anticancer activity and a unique mechanism of action (37, 
51). 
CONCLUSIONS
A growing body of evidence now supports the idea that TRAP1 
is associated with important human diseases including cancer 
and neurodegeneration (37, 42). However, the molecular regu-
latory mechanisms and signaling pathways affecting the chaper-
one functions are largely unknown at this point. Considering 
the dynamic chaperone complexes in the regulation of Hsp90 
in cytoplasm, there may be many unidentified post-translational 
modifications and protein interaction networks involving regu-
latory proteins or co-chaperones which modulate mitochon-
drial chaperones. Understanding the precise mechanisms of mi-
tochondrial chaperones can shed light not only on the molec-
ular mechanisms of mitochondrial transformation caused by 
disease onset and progression, but also the therapeutic value of 
mitochondria-targeted inhibitors in treating human diseases. 
Furthermore, considering the mitochondria-targeted delivery 
and direct induction of MMP, Gamitrinibs could sensitize the 
mitochondria to a variety of cell death stimuli using an entirely 
different mechanism from other cancer drugs. Thus, a combina-
tion treatment of Gamitrinibs with other anticancer drugs cur-
rently in the clinic should be considered to formulate better 
therapeutics to fight cancer.  
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